Sector News

Top-earning directors on the S&P 500?

December 18, 2015
Life sciences

Biopharma CEOs pull down some hefty pay packages, with Regeneron chief Len Schleifer topping the list last year at $42 million. But as lucrative as that may be, it’s not nearly as much as the highest-paid U.S. CEOs overall.

But biopharma board members? Many of them are collecting compensation that far outranks that of their peers.

According to Bloomberg, Regeneron’s 8 outside directors boasted average compensation of $1.9 million last year. The stock-and-cash packages made those directors the highest-paid on the Standard & Poor’s 500 Index.

Regeneron says it pays its directors so handsomely because the company itself is doing so well. So far this year, Regeneron shares are up 35%. Its Eylea drug has been one of the industry’s most successful launches this decade, and its drug-development projects in partnership with Sanofi count among the French drugmaker’s few R&D successes in recent years.

Its board met 7 times last year, Bloomberg says.

Regeneron is just one of the four biopharmas whose director pay ranked in the S&P 500’s top 10. Another drugmaker that pays its board members exceptionally well doesn’t have as much to brag about. That’s Endo International, whose outside directors made an average of $1.4 million, according to Bloomberg numbers.

Endo’s shares began 2015 at $72.51, and, at press time, were trading at $62.32. Its revenue for the 12 months ended Sept. 30 amounted to $3.35 billion–not so far short of Regeneron’s $3.81 billion for the same period–but its most recently quarterly growth was just 14%, compared with Regeneron’s 56%, according to Yahoo Finance stats.

The company has been struggling with generic competition to its Opana pain reliever, and fighting pay-for-delay lawsuits over its alleged attempts to keep copycat forms of that drug off the market. To expand its portfolio beyond its staple pain meds, Endo spent $8 billion in May to buy generics maker Par Pharmaceutical and its portfolio of injectable drugs.

Meanwhile, Vertex Pharmaceuticals shelled out $920,509 to its outside directors, on average, last year. Its shares stood at $117.80 Thursday, down from $119 at the beginning of the year, and its sales over the last 12 months amounted to $759 million, with 73% growth for Q3. The company recently won approval for its next-gen cystic fibrosis drug Orkambi, which is expected to give its top line a big boost, but its price is controversial at $259,000 annually. Its CEO, incidentally, ranked second on FiercePharma’s list of highest-paid in 2014, at $36.64 million in compensation.

As experts pointed out to Bloomberg, directors typically vote on their own pay with little pushback from shareholders. The danger of outsized compensation is that directors’ independence might be compromised. “Beyond the smell of self-dealing with their pay, directors may find their interests in getting the ongoing board fees a bit stronger than their willingness to rock the boat,” governance expert Gary Hewitt told the news service.

As Bloomberg also notes, not all directors are highly compensated. Warren Buffett’s Berkshire Hathaway, for instance, pays its outside board members $3,991 a year.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach